Gene Therapy Candidate Found to Provide Clinical Benefits for Up to 5 Years
PTC Therapeutics‘ gene therapy candidate PTC-AADC (formerly AGIL-AADC) provided clinically meaningful and sustained improvements in motor, cognitive, and language milestones in children with aromatic l-amino acid decarboxylase (AADC) deficiency up to five years following the one-time treatment, trial analyses show. A single dose of PTC-AADC delivered into…